DDInter770 DDInter704
Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database comprised of approximately 35,000 patients. It was launched in the US in December 1994 and in Japan in June 1999. As of the end of 1995, more than 10 million patients worldwide have been treated with fluvoxamine.
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Fluvoxamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Fluvoxamine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Everolimus
Fluvoxamine {u} (Compound) downregulates {v} (Gene) HERPUD1
HERPUD1 {u} (Gene) is upregulated by {v} (Compound) Everolimus
Fluvoxamine {u} (Compound) downregulates {v} (Gene) OXA1L
OXA1L {u} (Gene) is downregulated by {v} (Compound) Everolimus
Fluvoxamine {u} (Compound) causes {v} (Side Effect) Gastritis
Gastritis {u} (Side Effect) is caused by {v} (Compound) Everolimus
Fluvoxamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Pimecrolimus
Pimecrolimus {u} (Compound) resembles {v} (Compound) Everolimus
Fluvoxamine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Pimecrolimus
Pimecrolimus {u} (Compound) resembles {v} (Compound) Everolimus
Fluvoxamine {u} (Compound) downregulates {v} (Gene) HERPUD1
HERPUD1 {u} (Gene) is upregulated by {v} (Compound) Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Fluvoxamine {u} (Compound) downregulates {v} (Gene) OXA1L
OXA1L {u} (Gene) is downregulated by {v} (Compound) Tacrolimus
Tacrolimus {u} (Compound) resembles {v} (Compound) Everolimus
Fluvoxamine {u} (Compound) causes {v} (Side Effect) Gastritis
Gastritis {u} (Side Effect) is caused by {v} (Compound) Temsirolimus
Temsirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound)
Fluvoxamine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Everolimus (Compound)
Fluvoxamine (Compound) downregulates HERPUD1 (Gene) and HERPUD1 (Gene) is upregulated by Everolimus (Compound)
Fluvoxamine (Compound) downregulates OXA1L (Gene) and OXA1L (Gene) is downregulated by Everolimus (Compound)
Fluvoxamine (Compound) causes Gastritis (Side Effect) and Gastritis (Side Effect) is caused by Everolimus (Compound)
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Pimecrolimus (Compound) and Pimecrolimus (Compound) resembles Everolimus (Compound)
Fluvoxamine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Pimecrolimus (Compound) and Pimecrolimus (Compound) resembles Everolimus (Compound)
Fluvoxamine (Compound) downregulates HERPUD1 (Gene) and HERPUD1 (Gene) is upregulated by Sirolimus (Compound) and Sirolimus (Compound) resembles Everolimus (Compound)
Fluvoxamine (Compound) downregulates OXA1L (Gene) and OXA1L (Gene) is downregulated by Tacrolimus (Compound) and Tacrolimus (Compound) resembles Everolimus (Compound)
Fluvoxamine (Compound) causes Gastritis (Side Effect) and Gastritis (Side Effect) is caused by Temsirolimus (Compound) and Temsirolimus (Compound) resembles Everolimus (Compound)